December 4, 2020 - Fierce Biotech
Everlywell’s sales of at-home diagnostic tests, including one kit for COVID-19, are projected to quadruple this year—and investors have taken notice. The company’s second venture capital round this year has raised $175 million to help accelerate its efforts and expand further into retail stores nationwide.
December 4, 2020 - Fierce Biotech
Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes. The Seattle-based company had looked for a $100 million IPO last month but has got off a major $242 million debut, giving it a fully diluted market value of $758 million. In the end, it got this major cash swag by offering 11.5 million shares at $21, above the original range of $19 to $20.
December 3, 2020 - Fierce Pharma
Becton Dickinson masterminded the prefillable syringe, and decades later, it's a technology key to the global COVID-19 vaccine rollout. And with pandemic demand surging, BD is planning to shell out $1.2 billion to expand that very business.
December 3, 2020 - Fierce Pharma
Biologics production has mushroomed in recent years with massive investments from big biopharma and contract manufacturing alike. Just over a month after its parent company pledged to expand clinical supply of those drugs, a North Carolina-based CDMO has even bigger plans for its commercial ops.